Thomas Helleday's guest appearances

Thomas Helleday

Medical Sciences

Interviews with Oxonians

4th IMPAKT Breast Cancer Conference

Lewis Cantley

Larry Norton

Fabrice Andre

Richard Finn

Matthew Ellis

Martine Piccart

OwlTail

Prof Helleday talks to ecancer at the IMProving care And Knowledge through Translational research (IMPAKT) meeting in Brussels, May 2012, about novel therapies for triple negative breast cancer including the use of 6-mercaptopurine, previously not used in this group of patients.The plan is to tackle cells which have been resistant to cisplatin or PARP inhibitors; Prof Helleday discusses studies underway.

Prof Helleday talks to ecancer at the IMProving care And Knowledge through Translational research (IMPAKT) meeting in Brussels, May 2012, about novel therapies for triple negative breast cancer including the use of 6-mercaptopurine, previously not used in this group of patients.<br><br>The plan is to tackle cells which have been resistant to cisplatin or PARP inhibitors; Prof Helleday discusses studies underway.

Targeting DNA damage response and repair for triple negative breast cancer: Prof Thomas Helleday - Karolinska Institutet, Swede